GlassScriptPhysician profile
Matthew Hillis
NPI 1871184911
$7,677.77
in general payments reported to CMS, 2019-2025
25 companies · $4,801 in 2025
The $4,801 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.34 · 2024: $2,846 · 2025: $4,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,570 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,570.44 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,784.89 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,022.45 | 2024-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $715.34 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $674.91 | 2024-2025 | |
| Lilly USA, LLC | $402.62 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $401.22 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $382.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $364.09 | 2024-2025 | Zenpep |
| Genzyme Corporation | $361.06 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.69 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Ipsen Biopharmaceuticals, INC | $323.63 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $226.50 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $155.62 | 2024-2025 | Voquezna |
| Celgene Corporation | $74.95 | 2024 | Zeposia |
| Gilead Sciences, INC. | $72.64 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocon Biologics INC | $62.01 | 2025 | Yesintek |
| Ardelyx, INC. | $61.81 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $59.84 | 2024-2025 | |
| Medtronic, INC. | $43.87 | 2025 | Interstim |
| Novo Nordisk INC | $43.18 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $22.27 | 2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $17.13 | 2025 | |
| Sandoz INC. | $15.68 | 2025 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $15.30 | 2024 | |
| Merck Sharp & Dohme LLC | $15.26 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.